media – Pharma & Medical Industry Insights Hub | Drugdu Insights & Updates

Multiple batches of quadrivalent influenza virus split vaccine have been sub-packaged and submitted for lot release approval; expected to be released to the market soon after approval

Every Cabbage AI Express (NBD AI Express): An investor asked a question on the investor interaction platform: “Hello, Board Secretary. I saw that Chutian Technology mentioned that the vaccine appointment channels opened and immediately sold out. Is this a true reflection of the current influenza vaccine market? If so, why have the stock market performances of the company and its subsidiaries been lukewarm?” Hualan Bio (002007.SZ) replied on the investor interaction platform on December 11th that, according to public data from the National Institutes for Food and Drug Control (NIFDC), the company has obtained lot release approval for 55 batches of influenza vaccines so far this year, ranking among the top domestically in terms of the number of approved batches. Since October, and especially November, public awareness of influenza vaccination has significantly increased. Demand orders from CDCs (Centers for Disease Control and Prevention) across the country have risen significantly compared ...
- Source: drugdu
- 40
- December 12, 2025
Ab&B Bio-Tech CO., LTD. JS Lyophilized Human Rabies Vaccine Initiates Phase III Clinical Trials

On December 8, Zhaohui Bio-B (02627.HK) announced that the company recently initiated Phase III clinical trials for its lyophilized human rabies vaccine (human diploid cell). The development of this vaccine aims to target three immunization schedules. A new drug clinical trial license was approved by the National Medical Products Administration of the People’s Republic of China (NMPA) in November 2022, followed by the approval of supplementary clinical trial applications for the Zagreb (four-dose) and simplified four-dose regimens in April 2023. The company completed the Phase I clinical trial of this investigational vaccine in October 2024. Rabies is a serious viral disease caused by the rabies virus, and appropriate vaccination can effectively prevent it. Rabies vaccines developed using human diploid cells are recommended by the WHO as the “gold standard” due to their favorable safety characteristics. Although the company demonstrated good safety in the Phase I clinical trials, the announcement also ...
- Source: drugdu
- 39
- December 12, 2025
The ‘Sweetest’ HPV Vaccine Market is Gone | Haibin Interview

This week, the nine-valent HPV vaccine of Wantai Biological was launched in Shanghai. The curtain has risen on the competition between Wantai Biological and Merck in the field of nine-valent HPV vaccines. The HPV vaccine is of great significance in preventing diseases such as cervical cancer and saving tens of thousands of lives. At present, only these two enterprises have launched the nine-valent vaccine in China. Previously, Merck had monopolized this market for seven years, taking away the most profitable portion of it. Now, Merck’s agent, Zhifei Biological, has accumulated too much inventory. Wantai Bio has leveraged the price-sensitive market with lower prices. But now the commercial returns of vaccine enterprises are becoming increasingly unclear, especially for those whose products are still in the clinical stage. The problem facing some enterprises is whether the ongoing clinical trials of bivalent and nonavalent HPV vaccines should be halted. The nine-valent vaccine is ...
- Source: drugdu
- 38
- December 12, 2025
InnoCare Pharma announced that its first independently developed next-generation TRK inhibitor, zoletrazinib, has been approved for marketing in China

In a pivotal registrational clinical trial for patients with NTRK fusion-positive solid tumors, zoletrazinib demonstrated efficacy and safety as a broad-spectrum anticancer drug regardless of tumor type. The registrational clinical trial results showed an overall response rate (ORR) of 89.1%, a disease control rate (DCR) of 96.4%, a 24-month progression-free survival (PFS) rate of 77.4%, and a 24-month overall survival (OS) rate of 90.8%. As a new generation TRK inhibitor independently developed in China, zoletrazinib is more effective than first-generation TRK inhibitors. It not only provides long-term deep remission but also exhibits strong penetrating brain activity and good overall safety. Furthermore, data shows that it can overcome resistance to first-generation TRK inhibitors. The once-daily oral administration of two tablets also offers greater convenience to patients. Professor Zhang Yizhuo of Sun Yat-sen University Cancer Center believes that NTRK fusion-positive tumors often progress rapidly and have limited treatment options. Zoletratinib has demonstrated ...
- Source: drugdu
- 36
- December 12, 2025
Is PD-1/VEGF dual antibody + ADC becoming the standard configuration?

The latest entrants are Kolen Biotech and Crescent. Recently, the two companies reached a unique licensing agreement, mutually introducing each other’s core pipeline assets and jointly joining the PD-1/VEGF+ADC development camp. The collaboration between Kelun Biotech and Crescent can be seen as a small and medium-sized player quickly following the lead of giants in this game. Core players such as BioNTech/BMS, 3SBio/Pfizer are laying out their strategies and competing in this field. It is not difficult to see from their clinical development strategies that the combination of PD-1(L1)/VEGF bispecific antibodies and ADCs is upgrading from “exploration” to “standard”. Just a few months ago, global pharmaceutical companies were hunting down PD-(L)1/VEGF bispecific antibodies, driving up the prices of these assets. Now, with the trend of PD-(L)1/VEGF bispecific antibodies accelerating their iteration into monoclonal antibodies confirmed, MNCs have been aggressively pursuing these acquired assets, and the “battleground” has shifted to the competition ...
- Source: drugdu
- 38
- December 12, 2025
Another “disaster” for pre-antibody technology

Recently, Janux Therapeutics, which focuses on proantibody technology, saw its stock price plummet by 53.34% after releasing the latest clinical data for its core product JANX007. This bispecific antibody prodrug targeting PSMA/CD3 initially impressed the market with its 50% ORR (Objective Response Rate) data released in December 2024, causing the company’s stock price to surge by nearly 50% in a single day and its market capitalization to once exceed $3.5 billion. It was seen as the hope for a breakthrough in proantibody technology. However, a year later, as the sample size expanded from 16 to 104 cases, the ORR plummeted from 50% to 30%, the PSA90 response rate shrank from 63% to 26%, and the safety performance also fell short of expectations. More noteworthy is that this is not the first time the antibody field has encountered a major setback. Back in 2022, CytomX Therapeutics, a pioneer in antibody technology, ...
- Source: drugdu
- 35
- December 12, 2025
Eding Medicines’ NexGard® showcased 11 Chinese clinical studies at APCN 2025, solidifying its position as a cornerstone of first-line treatment for IgA nephropathy

At the 23rd Asia Pacific Nephrology Congress (APCN 2025) recently, Everest Medicines’ core product, NEFECON® (budesonide enteric-coated capsules), showcased 11 of the latest clinical research data from several top hospitals in China, providing more evidence-based medical support for the treatment of IgA nephropathy. IgA nephropathy is a prevalent chronic kidney disease in Asia, with approximately 5 million patients in China and over 120,000 new diagnoses annually. This disease is characterized by high incidence and high progression rates, highlighting the urgent need for precise clinical treatment. Following the inclusion of the world’s first etiological treatment drug, Nefucon®, in my country’s national medical insurance program, clinicians have gradually shifted their focus from improving proteinuria to protecting kidney function as treatment duration accumulates, aiming to provide important insights for the long-term management of IgA nephropathy patients. The numerous studies presented at this conference, from different clinical scenarios and long-term treatment perspectives, further enriched ...
- Source: drugdu
- 33
- December 12, 2025
Innovent Biologics’ new BCL2 inhibitor, Mesutoclax, shines with the latest clinical data at the 67th American Society of Hematology (ASH) Annual Meeting

Beijing, China, December 9, 2025 – Innovent Biologics (SSE: 688428; HKSE: 09969), a high-tech biopharmaceutical company, today announced that three studies of its novel BCL2 inhibitor, mesutoclax (ICP-248), were presented at the 67th American Society of Hematology (ASH) Annual Meeting. Mesutoclax demonstrated excellent efficacy and safety in studies treating relapsed/refractory mantle cell lymphoma (MCL), chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), and acute myeloid leukemia (AML). Studies of mesutoclax in the treatment of relapsed/refractory MCL were selected for oral presentations, and two studies of mesutoclax in the treatment of CLL/SLL and AML were selected for poster presentations. oral report Efficacy and tolerability of Mesutoclax monotherapy in patients with relapsed/refractory MCL: High response rate demonstrated in patients previously resistant to BTK inhibitors (Report No.: 887) Mesutoclax monotherapy has demonstrated excellent efficacy in treating MCL patients, particularly in previously treated patients refractory to BTK inhibitors. The overall response rate (ORR) for MCL patients ...
- Source: drugdu
- 31
- December 12, 2025
Lilly’s Retatrutide Displays Positive Topline Results in Successful Phase III Trial

Lilly’s first Phase III results for retatrutide show unprecedented weight loss and marked reductions in osteoarthritis pain, underscoring the potential of its triple-agonist therapy to reshape treatment for obesity and related metabolic conditions. Eli Lilly and Company announced positive results from its Phase III trial study TRIUMPH-4 showing that retatrutide produced substantial weight loss and showed reductions in knee pain for adults with obesity or overweight and knee osteoarthritis. Retatrutide is a once-weekly investigational molecule that activates receptors for GIP, GLP-1, and glucagon. TRIUMPH-4, a global, randomized study, evaluated retatrutide’s two highest doses, 9 mg and 12 mg, over a 68 week period.1 In the trial, where most participants had a body mass index (BMI) of at least 23.5 lbs/ft² at baseline, both doses met all primary and key secondary endpoints, with patients receiving the 12 mg dose losing an average of 28.7% of their body weight, more than 70 ...
- Source: drugdu
- 39
- December 12, 2025
FDA Reviewing RSV Drugs for Infants, Though No Safety Issues Found

THURSDAY, Dec. 11, 2025 (HealthDay News) — Federal regulators have begun a safety review of two RSV medicines used to protect infants, even though no safety problems have been reported. The review covers Beyfortus (from Sanofi and AstraZeneca) and Enflonsia (from Merck), both monoclonal antibodies that help shield babies from respiratory syncytial virus, or RSV. The move comes as several immunizations have faced new scrutiny under U.S. Health Secretary Robert F. Kennedy Jr. The U.S. Food and Drug Administration (FDA) said it is taking a close look at all available data, as it does with any approved product. The agency is “rigorously reviewing the available data, as it does for all products, to ensure decisions remain rooted in evidence-based science and in the best interest of patients,” HHS spokesperson Andrew Nixon said. Drugmakers say the treatments have strong safety records. Sanofi told NBC News that Beyfortus has been studied in ...
- Source: drugdu
- 40
- December 12, 2025

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.